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Abstract 53 
Introduction: Infected pancreatic necrosis (IPN) and its related septic complications 54 
are the major causes of death in patients with acute necrotizing pancreatitis (ANP). 55 
Therefore, the prevention of IPN is of great clinical value, and immunomodulatory 56 
therapy with Thymosin Alpha 1 may be beneficial. This study was designed to test the 57 
hypothesis that the administration of Thymosin Alpha 1 during the acute phase of ANP 58 
will result in a reduced incidence of IPN.  59 
Methods and analysis: This is a randomized, multicenter, double-blind, placebo-60 
controlled study. 520 eligible ANP patients will be randomized in a 1:1 ratio to receive 61 
either the Thymosin alpha 1 or the placebo using the same mode of administration. The 62 
primary endpoint is the incidence of IPN during the index admission. Most of the 63 
secondary endpoints will be registered within the index admission including in-hospital 64 
mortality, the incidence of new-onset organ failure and new-onset persistent organ 65 
failure (respiration, cardiovascular and renal), receipt of new organ support therapy, 66 
requirement for drainage or necrosectomy, bleeding requiring intervention, HLA-DR 67 
on day0, day7, and day14, etc., and adverse events. Considering the possibility of 68 
readmission, an additional follow-up will be arranged 90 days after enrollment, and 69 
IPN and death at Day90 will also be served as secondary outcomes.  70 
Ethics and dissemination: This study was approved by the ethics committee of Jinling 71 
Hospital, Nanjing University (No. 2015NZKY-004-02). The TRACE trial was designed 72 
to test the effect of a new therapy focusing on the immune system in preventing 73 
secondary infection following ANP. The results of this trial will be disseminated in peer-74 
reviewed journals and at scientific conferences. 75 
Trial registration：The trial has been registered at the ClinicalTrials.gov registry 76 
(NCT02473406) 77 
Strengths and limitations of this study 78 
Strength 1：This is a randomized, multicenter, double-blind, placebo-controlled trial 79 
providing top-class evidence concerning the efficacy and safety of thymosin alpha 1 for 80 
patients with acute necrotizing pancreatitis. 81 
Strength 2: The data will be handled by an independent data safety monitoring board 82 
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(DSMB) to ensure the safety of the participants. 83 
Strength 3: Thymosin alpha 1 is a well-studied drug with a favorable safety profile in 84 
previous trials.  85 
Limitation 1: A sample size of 520 is required to detect the efficacy of Thymosin Alpha 86 
1 in preventing infected pancreatic necrosis, which will take years before the conclusion 87 
could be drawn. 88 
Limitation 2: Continuous immune function assessment is not applied in this study.  89 
  90 
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Background 91 
Infected pancreatic necrosis (IPN) and its related septic complications contribute 92 
substantially to deaths in patients with acute necrotizing pancreatitis(ANP)[1]. 93 
Compared with patients with sterile necrosis, those with IPN suffered a significant 94 
increase in mortality ranging from 14% to 69%, despite advances in critical care, 95 
surgical and endoscopic interventions, and antibiotics[2]. Therefore, the prevention of 96 
IPN is of great clinical value in the treatment of ANP. Over the past years, numerous 97 
attempts had been made to prevent or delay the development of IPN, including 98 
antibiotic prophylaxis, early enteral nutritional, selective gut decontamination, and 99 
probiotics. Still, none of them had been proved to improve patient-centered outcomes 100 
with high-quality evidence [3-6]. More promising treatment aiming at reducing 101 
infectious complications of ANP is in need.  102 
Immunosuppression and disorders characterized by decreased HLA-DR expression 103 
and unbalanced CD3/CD4+/CD8+ T cells of peripheral blood mononuclear cell are 104 
reported to be associated with IPN[7, 8], especially in those with a more severe type of 105 
disease, whose suppressed immune function occurs early and strongly[8, 9]. Our 106 
previous observational study found that early enteral nutrition could moderate the 107 
excessive immune response during the acute phase of severe acute pancreatitis without 108 
leading to subsequent immunosuppression, and ultimately reduce the incidence of 109 
infection and ICU stay [10]. Thus, immunomodulatory treatment could potentially 110 
intervene in the development of IPN, resulting in better outcomes. Efforts had been 111 
made in this field using drugs like lexipafant and octreotide. Still, the hitherto existing 112 
evidence failed to show robust clinical benefits of immunomodulation with regard to 113 
key clinical outcomes [11].  114 
Thymosin alpha 1 had been shown to have immunomodulatory properties and was 115 
reported to be clinically beneficial in patients with sepsis[12, 13], majorly through the 116 
involvement of distinct Toll-like receptors acting on different dendritic cells subsets and 117 
involving the MyD88-dependent signaling pathway. However, for acute pancreatitis 118 
(AP), the only randomized controlled study was the pilot one conducted by our group 119 
years ago, suggesting that the use of Thymosin alpha 1 was associated with improved 120 
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cellular immunity and reduced infection rate in a group of 24 patients[14]. Due to the 121 
single-center set and small sample size, the clinical implication and generalizability of 122 
this study are thought to be limited. Therefore, we designed this multicenter trial, the 123 
Thymosin Alpha 1 in the Prevention of Infected Pancreatic Necrosis Following Acute 124 
Necrotizing Pancreatitis (TRACE), with sufficient power to test the hypothesis that the 125 
administration of Thymosin Alpha 1 during the acute phase of ANP will result in a 126 
reduced incidence of IPN.  127 
 128 
Study objectives  129 
The primary objective of the TRACE trial is to determine whether Thymosin Alpha 130 
1 is superior to placebo in reducing the incidence of IPN in patients with ANP. 131 
Secondary objectives are to determine the safety and the impact on the immune function 132 
of Thymosin Alpha 1 among patients with ANP. 133 
 134 
Study Design 135 
The present study is an investigator-initiated, multicenter, individually-randomized, 136 
double-blind, placebo-controlled, parallel-group study. This trial was registered on June  137 
16th, 2015, in the CT.gov registry (NCT02473406, https://www.clinicaltrials.gov/) and 138 
was approved by the ethics committee of Jinling Hospital, Nanjing University (No. 139 
2015NZKY-004-02). Local ethics approval was also obtained before enrollment in each 140 
participating center. The TRACE trial was designed and coordinated by the Center of 141 
Severe Acute Pancreatitis at Nanjing University and the coordinating and data 142 
management center of the Chinese Acute Pancreatitis Clinical Trials Group (CAPCTG). 143 
The trial steering committee (TSC) was formed to oversee the implementation of the 144 
study, and a data safety monitoring board (DSMB) will regularly (every six months) 145 
review the safety report prepared by the trial statistician from the accumulating data of 146 
this trial. 147 
 148 
Study population 149 
This trial is performed in 16 hospitals from China. All adult patients with AP admitted 150 
to the participating centers will be assessed for eligibility after admission. The inclusion 151 
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and exclusion criteria are as follows: 152 
Inclusion criteria 153 
1. Symptoms and signs of AP based on abdominal pain suggestive of AP, serum amylase 154 
at least three times the upper limit of normal, and/or characteristic findings of AP on 155 
computed tomography or less commonly magnetic resonance imaging (MRI) or 156 
transabdominal ultrasonography according to the Revised Atlanta Criteria[15];  157 
2. Less than one week from the onset of abdominal pain;  158 
3. Age between 18 to 70 years old;  159 
4. Acute Physiology and Chronic Health Evaluation(APACHE II) score ≥eight during 160 
the last 24 hours before enrollment 161 
5. Balthazar CT score ≥5 (presence of pancreatic necrosis)[16]. 162 
6. Written informed consent obtained 163 
Exclusion criteria  164 
1. Pregnant pancreatitis; 165 
2. History of chronic pancreatitis； 166 
3. Malignancy related acute pancreatitis  167 
4. Receiving early intervention or surgery due to abdominal compartment syndrome 168 
or other reasons before admission； 169 
5. Patients with a known history of severe cardiovascular, respiratory, renal or hepatic 170 
diseases defined as (1) greater than New York Heart Association Class II heart 171 
failure(Class II not included), (2) active myocardial ischemia or (3) cardiovascular 172 
intervention within previous 60 days, (4) history of cirrhosis or (5) chronic kidney 173 
disease with creatinine clearance< 40 mL/min, or (6) chronic obstructive pulmonary 174 
disease with the requirement for home oxygen;  175 
6. Patients with preexisting immune disorders such as AIDS. 176 
  A patient will be considered eligible if he/she meets the inclusion criteria and does 177 
not meet any of the exclusion criteria. Allocation will be performed after signed consent 178 
is obtained. The study protocol flow of participants is outlined in Figure 1. 179 
 180 
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Randomization and blinding methods 181 
After the completion of screening measurements and the acquisition of written 182 
informed consent, eligible participants will be randomized in a 1:1 ratio to either the 183 
treatment group or the placebo group. The randomization code was computer-generated 184 
with a block size of 4, and the randomization was stratified by sites. 185 
Participants, clinical investigators, and investigators assessing outcome data will be 186 
blinded to the treatment allocation to minimize potential sources of bias. The trial 187 
statistician will also be blinded regarding the treatment code when developing the 188 
statistical programs, which will be validated and completed using dummy 189 
randomization codes. The actual allocation will only be provided to the study team after 190 
locking of the database and approval of the statistical analysis plan. 191 
 192 
Trial drugs  193 
After randomization, the participant will receive: 194 
1. Thymosin Alpha 1 1.6mg I.H q12h for the first seven days and 1.6mg I.H, qd 195 
for the following seven days. The administration will be terminated any day 196 
during the treatment when the patient is deemed as qualified for hospital 197 
discharge, or dead. 198 
2. Matching placebo(normal saline) using the same mode of administration as 199 
the above mentioned. 200 
As shown in Figure 1, the recruited patients will start to receive randomized drugs 201 
subcutaneously from the day after the allocation day. Thymosin Alpha will be provided 202 
by SciClone Pharmaceuticals and the matching placebo by Chengdu Tongde 203 
Pharmaceuticals. All study drugs will be stored in a secure area with access limited to 204 
the investigators and authorized study site personnel, and under appropriate storage 205 
conditions. 206 
 207 
General treatment regimen 208 
All patients will receive standard treatment including fluid therapy, early enteral 209 
nutrition, routine medical treatment like proton pump inhibitor as indicated, mechanical 210 
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ventilation if needed, and continuous renal replacement therapy (CRRT) if needed in 211 
the light of recently published guidelines[17]. All participating centers are able to offer 212 
appropriate intensive care in case the patients require organ support or continuous 213 
monitoring. The necrotic collection will be intervened when infection is suspected or 214 
confirmed, preferably after four weeks from the onset of the disease when the patient 215 
could tolerate the symptoms as suggested by the guidelines[17].  216 
When pancreatic infection occurs, either a surgical or endoscopic step-up approach 217 
considering the location of the necrotic collection and the technical availability in each 218 
participating center will be applied. Principally, either percutaneous catheter drainage 219 
or endoscopic transluminal placement of double pig-tail stents，rather than debridement, 220 
are the primary choices of treatment.  221 
 222 
Endpoints 223 
Primary outcome measure 224 
The incidence of IPN during the index admission will be served as the primary 225 
outcome measure of the TRACE trial. The diagnosis of IPN will be based on the 226 
international guidelines when one or more of the following were present: gas bubbles 227 
within (peri) pancreatic necrosis on computed tomography; a positive culture of (peri) 228 
pancreatic necrosis obtained by image-guided fine-needle aspiration; a positive culture 229 
of (peri) pancreatic necrosis obtained during the first drainage and/or necrosectomy[15]. 230 
Secondary outcome measures 231 
Part I：Secondary outcomes during the index admission 232 
1. The occurrence of new-onset organ failure and new-onset persistent organ failure 233 
(SOFA score for respiration, cardiovascular, or renal system ≥2 ). New-onset is 234 
defined as events that occur after randomization and not present 24 hours before 235 
randomization;  236 
2. In-hospital mortality; 237 
3. Bleeding requiring intervention； 238 
4. Gastrointestinal perforation or fistula requiring intervention; 239 
5. Incidence of pancreatic fistula 240 
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6. New receipt of mechanical ventilation (not applied 24 hours before 241 
randomization); 242 
7. New receipt of renal replacement therapy (not applied 24 hours before 243 
randomization); 244 
8. New receipt of vasoactive agents (not applied 24 hours before randomization); 245 
9. The requirement for catheter drainage (either percutaneous or endoscopic) 246 
10. Number of drainage procedures required; 247 
11. The requirement for minimally-invasive debridement; 248 
12. Number of minimally invasive necrosectomy required; 249 
13. The requirement for open surgery; 250 
14. Number of open operations required; 251 
15. Length of intensive care unit(ICU) stay;  252 
16. Length of hospital stay; 253 
17. SOFA score on day0, day7, and day14； 254 
18. CRP level on day0, day7, and day14; 255 
19. HLA-DR level on day0, day7, and day14; 256 
20. Lymphocyte count on day0, day7 and day 14;  257 
21. In-hospital cost. 258 
Part II：Secondary outcomes within 90 days after enrollment   259 
1. Incidence of infection within 90 days after enrollment； 260 
2. Mortality within 90 days after enrollment. 261 
 262 
Sample size estimation  263 
The incidence of IPN during the index admission was reported to be around 25% in 264 
ANP episodes combined with an APACHE II score≥8 in our previous studies[18, 19]. 265 
To reduce the incidence of IPN from 25% to 15% on the basis of our pilot study [14], 266 
we projected a sample size of 500 participants with 80% power at a two-sided alpha 267 
level of 0.05 using the PASS software (PASS 11, NCSS software, Kaysville, USA). In 268 
our study, we planned to randomize 520 patients after considering 4% of lost follow up.  269 
 270 
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Statistical analysis 271 
Primary analyses will be based on the intention-to-treat (ITT) population, and 272 
secondary supportive analyses will be done on the PP population. The safety analysis 273 
will be performed on the safety population. Missing data will be handled by multiple 274 
imputations to evaluate the robustness of the primary endpoint analyses[20]. The 275 
populations are defined as follows: 276 
1. ITT population: This population consists of all randomized subjects, regardless of 277 
whether they are ineligible, prematurely discontinue treatment, or are otherwise 278 
protocol violators/deviators.  279 
2. Per-protocol (PP) population: This population is a subset of the ITT population. 280 
Subjects with major protocol deviations will be excluded from the PP population. 281 
Major protocol deviations will be defined in the statistical analysis plan.  282 
3. Safety population: This population will be the same as the ITT population, which 283 
consists of all randomized subjects, who receive at least one dose of study drug. 284 
The normality of continuous variables was examined using skewness and kurtosis. 285 
Categorical data were expressed as number and percentage. A generalized linear 286 
model (GLM) will be employed to compare group differences in the primary outcome. 287 
No interim analysis was planned in our study. The detailed analysis strategies for 288 
secondary outcomes and subgroup analyses by the severity of AP(severe and non- 289 
severe), age(dichotomized at 60 years old), etiologies of AP (biliary and non-biliary) 290 
and extent of pancreatic necrosis(>50% and ≤50%), will be included in the statistical 291 
analysis plan. Statistical tests will be two-sided, and p values < 0.05 will be deemed as 292 
significant.  293 
 294 
Adverse events 295 
Adverse events (AEs) are defined in accordance with the National Cancer Institute-296 
Common Terminology Criteria for Adverse Events as any untoward medical occurrence 297 
in a patient, or clinical investigation subject administered an investigational 298 
intervention and which does not necessarily have to have a causal relationship with this 299 
treatment. 300 
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It is recognized that the study patient population (ANP with relatively high APACHE 301 
II score) will experience a number of common aberrations in laboratory values, signs, 302 
and symptoms due to the severity of the underlying disease and the impact of standard 303 
therapies. These will not necessarily constitute an adverse event unless they require 304 
significant intervention or are considered to be of concern in the investigator’s clinical 305 
judgment. Thymosin alpha 1 is a well-studied drug with a favorable safety profile in 306 
previous trials [21]. The DSMB will review the safety report every six months. 307 
 308 
Recruiting process 309 
The trial was registered on June 16th, 2015, in the CT.gov registry(NCT02473406 310 
https://www.clinicaltrials.gov). The first patient was randomized on March 22nd, 2017. 311 
So far, 426 patients had been randomized, and the enrollment keeps to the schedule. 312 
 313 
Patient and Public Involvement 314 
Patients or the public were not involved in the design, or conduct, or reporting, or 315 
dissemination plans of our research. 316 
 317 
Data collection and management 318 
A web-based electrical database (access through the website of the CAPCTG, 319 
https://capctg.medbit.cn/) will be used for data collection and storage. All data will be 320 
input by the primary investigator or nominated investigators (less than two for each 321 
participating center) approved by the primary investigator, and a double check will be 322 
done by the research coordinator. Training for data entry will be performed by the 323 
provider of the electrical database (Unimed Scientific Inc., Wuxi, China) and the 324 
coordinating and data management center of the CAPCTG. According to the schedule 325 
shown in Figure 2, the investigator will collect data during the index admission and on 326 
day 90 after enrollment. If a study subject wishes to discontinue the study drug or the 327 
treating physician believes a study subject should discontinue the study drug due to 328 
medical considerations, the investigator will communicate with the study subject and 329 
the treating physician to obtain the reasons. Further evaluation and follow-up will still 330 
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be performed unless the study subject withdraws consent for disclosure of information. 331 
The study blinding will only be broken in a medical emergency when the treating 332 
physician believes that the administration of the study drug is associated with the 333 
emergency. 334 
 335 
Ethics approval and dissemination  336 
This study was approved by the ethics committee of Jinling Hospital. The ethical 337 
approval document ID is 2015NZKY-004-02. Even when central ethical approval has 338 
been confirmed, we will not begin recruiting at other participating centers in the trial 339 
until the local ethics committee approved the study. Site ethical approvals were obtained 340 
from ethics committees of First Affiliated Hospital of Nanchang University, The 341 
Affiliated Hospital of Qingdao University, Affiliated Hospital of Zunyi Medical 342 
College, Nanhua Hospital, Second Affiliated Hospital of Nantong University, Yijishan 343 
Hospital of Wannan Medical College, 908th Hospital of Chinese People’s Liberation 344 
Army, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, 345 
Zhejiang Provincial People's Hospital, Luoyang Central Hospital, The Affiliated 346 
Hospital of Henan University of Science and Technology, Northern Jiangsu People’s 347 
Hospital, First People's Hospital of Shangqiu, Qilu Hospital of Shandong University, 348 
and First Affiliated Hospital of Anhui Medical University. The results of this trial will 349 
be reported in peer-reviewed journals and presented at scientific conferences. 350 
 351 
Consent to participate 352 
The consents for this study is obtained from each patient or his/her next of kin with 353 
full information regarding the possible adverse effects of the experimental drug and 354 
potential consequences. The translated patient consent form is attached as a 355 
supplemental file( Supplement Materials).   356 
 357 
Discussion 358 
The TRACE trial was designed to test the efficacy of a new therapy targeting the 359 
immune system in preventing IPN following ANP, which is a potentially lethal 360 
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complication causing substantial morbidity and mortality. We also aimed to investigate 361 
the efficacy of immunomodulatory treatment with thymosin alpha 1 in patients with 362 
different clinical characteristics using predefined subgroup analysis. The results of the 363 
TRACE trial would potentially provide a novel therapeutic option in the management 364 
of ANP and identify the patient population who may benefit most from the 365 
administration of thymosin alpha 1.  366 
Immunomodulation is of significant clinical value in critically ill settings and the 367 
treatment of sepsis[12]. While, acute pancreatitis, which has a lot in common with 368 
sepsis like overwhelmed inflammation and infection related complications, might be 369 
another suitable target for immunomodulatory therapy. In general, previously studied 370 
drugs such as lexipafant and octreotide were aimed to control cytokines, which are 371 
thought to be the pivotal part in the early inflammatory response of AP, rather than 372 
preventing the development of IPN[11]. However, like what we learned in sepsis, 373 
immunosuppression quickly following the initial inflammatory cascades should be the 374 
target of treatment during the course of ANP, as well, especially in those with organ 375 
failure[8, 22]. A pilot study published by our group several years ago indicated that the 376 
administration of thymosin alpha 1 could improve compromised monocyte HLA-DR 377 
expression and reduce infection rate in a small group of patients (n=24) with severe 378 
acute pancreatitis defined by the original Atlanta Classification. The result of this study 379 
is encouraging which drive us to conduct this large multi-center RCT to obtain more 380 
reliable clinical evidences[14]. 381 
The TRACE trial was sponsored by the CSAP at Jinling Hospital, Nanjing University, 382 
which is the national referral center for acute pancreatitis (AP) admitting more than 600 383 
cases of AP annually and coordinated by the CAPCTG coordinating and data 384 
management center, which could cover the whole country. The trial is performed in 16 385 
centers across China and aims to recruit 520 patients. Due to the limitation of the budget 386 
and technical availability, we can not conduct a continuous immune assessment with 387 
multiple markers and more time points. Alternatively, we choose monocyte HLA-DR, 388 
which is a representative parameter of the immune system, majorly reflecting the 389 
antigen presentation capacity to assess the immunomodulatory effect of thymosin alpha 390 
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1. HLA-DR was widely used in previous studies regarding immune function in different 391 
diseases like sepsis[12, 23].  392 
In conclusion, the TRACE trial aims to assess the efficacy of thymosin α1 393 
administered early during the ANP on the incidence of IPN and other major clinical 394 
outcomes and thereby potentially offer a novel therapeutic option in the treatment of 395 
ANP patients.  396 
 397 
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Figure 2. Schedule for participants enrolment, drug administration, and data collection. 453 
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